ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2183 • ACR Convergence 2023

    Evolution of Lymphoma Predictors in Primary Sjogren’s Syndrome by Data Driven Analysis in Harmonized Patients

    Andreas Goules1, Loukas Chatzis2, Vasileios pezoulas3, Francesco Ferro4, Valeria Manfrè5, Dimitrios Fotiadis3, Luca Quartuccio Quartuccio6, Chiara Baldini7, Salvatore De Vita5 and Athanasios Tzioufas1, 1Dept. of Pathophysiology, School of Medicine, University of Athens, Athens, Greece, 2Dept. of Pathophysiology, School of Medicine, University of Athens, Cholargos Athens, Greece, 3Unit of Medical Technology and Intelligent Information Systems, Dept. of Materials Science and Engineering, University of Ioannina, Ioannina, Greece, 4Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 5Clinic of Rheumatology, Dept. of Medical and Biological Sciences, Udine University, Udine, Italy, 6Rheumatology Division, Department of Medicine, University of Udine, Udine, Italy, 7University of Pisa, Pisa, Italy

    Background/Purpose: Lymphoma is the most serious complication of primary Sjogren'ssyndrome (pSS), occurring as a late sequel during disease course. So far, lymphomapredictors have been identified…
  • Abstract Number: 1723 • ACR Convergence 2023

    3,3-dimethyl-1-butanol and Its Metabolite 3,3-dimethylbutyrate Ameliorate Arthritis Severity in CIA Independent of Choline TMA Lyase Activity

    Brendan Allen1, Sabrina Fechtner2, Meagan Chriswell3, Widian Jubair1, M. Aaron Vrolijk1, V. Michael Holers4 and kristine Kuhn1, 1University of Colorado School of Medicine, Aurora, CO, 2University of Colorado Anschutz Medical Campus, Aurora, CO, 3University of Colorado Anschutz SOM, Denver, CO, 4University of Colorado, Denver, CO

    Background/Purpose: Both human and animal studies associate specific microbiota and microbial metabolic pathways with the development of RA and autoimmune arthritis, thereby providing a novel…
  • Abstract Number: 2187 • ACR Convergence 2023

    Association Between Illness Perception, Anxiety and Depression State, Disease Activity and Glucocorticoid Therapy in Patients with Sjӧgren’s Syndrome

    Chiara Baldini1, Elena Elefante2, Inmaculada Conception Navarro Garcia2, Francesco Ferro3, Gaetano La Rocca4, Giovanni Fulvio1, Silvia Fonzetti5, Michele Moretti6 and Marta Mosca2, 1University of Pisa, Pisa, Italy, 2Rheumatology Unit, Department of clinical and experimental medicine, University of Pisa, Pisa, Italy, 3Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, 4University of Pisa, Rheumatology Unit, Pisa, Italy, 5AOUP, Pisa, Italy, 6Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy

    Background/Purpose: Sjӧgren's syndrome (SS) may affect several aspects of patients' daily lives, leading to impairment of quality of life and patient functioning. Aims of this…
  • Abstract Number: 2188 • ACR Convergence 2023

    Lung Cysts in Primary SS: New Findings on an Allegedly Innocuous Iiagnosis

    Regis Sewa Marques, Maria Fernanda Zacarin, Pamela Bellini, Raissa Dudienas D Pereira, Aloma Guinami Scabora, Zoraida Sachetto, Manoel Bertolo and ALISSON PUGLIESI, Universidade Estadual de Campinas, Campinas, Brazil

    Background/Purpose: Lung cysts are a frequent finding in patients with SS, with previous data indicating a prevalence of approximately 30% on chest CT scans. In…
  • Abstract Number: 1739 • ACR Convergence 2023

    Mass Spectrometry Identified Rheumatoid Arthritis-Specific Modified Proteins and the Discovery of Antigen-Specific Hidden Autoantibodies

    Khetam Ghannam1, Marieluise Kirchner2, Holger Bang3, Thomas Häupl4, Sarah Ohrndorf1, Jan Zernicke1, Ulrike Kuckelkorn5, Philipp Mertins6, Eugen Feist7 and Gerd Burmester8, 1Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, 2Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 3Orgentec Diagnostika GmbH, Mainz, Germany, 4Helios Department of Rheumatology, Vogelsang-Gommern, Germany, 5Institute of Biochemistry, Berlin, Germany, 6Proteomics Platform at Max Delbrück Center for Molecular Medicine and Berlin Institute of Health (BIH), Berlin, Germany, 7Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 8Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease characterized by synovial inflammation and progressive joint destruction. Given the presumed pathophysiologic role of…
  • Abstract Number: 1733 • ACR Convergence 2023

    Platelet-Derived Growth Factor Is a Mediator of Disease in an Animal Model of Rheumatoid-Associated Interstitial Lung Disease

    Nozima Aripova1, Michael Duryee1, Amy Nelson1, Carlos Hunter1, Breanna Butler1, Bryant England1, Jill Poole1, Geoffrey Thiele1 and Ted R Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a leading cause of mortality in RA with limited treatment options as well as lack of available…
  • Abstract Number: 2182 • ACR Convergence 2023

    Mitochondrial Alterations in Primary Sjögren´s Syndrome

    Pavlina Javorova1, Johannes Fessler1, Melanie Zeiler1, Angelika Lackner1, Josef Hermann2, Sabine Zenz3, Jens Thiel4 and Martin Stradner1, 1Medical University of Graz, Graz, Austria, 2Division of Rheumatology and Immunology, Department of Internal Medicine, Medical University Graz, Graz, Austria, 3Medical University Graz, Graz, Austria, 4University Hospital Freiburg, Freiburg, Germany

    Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic autoimmune disorder characterized by lymphocytic infiltrations in exocrine glands. T-cells are considered major players in the pathogenesis…
  • Abstract Number: 2186 • ACR Convergence 2023

    Neurological Complications in Sjögren’s: Occurrence & Impact on Patient Quality of Life

    Matt Makara, Janet Church and Katherine Hammitt, Sjögren’s Foundation, Reston, VA

    Background/Purpose: Sjögren's is a serious and systemic autoimmune disease that affects the entire body, including the nervous system. This study aimed to better understand the…
  • Abstract Number: 1574 • ACR Convergence 2023

    The Role of 18F-FDG PET/CT Scans in Takayasu Arteritis

    Sahil Jain1, Abdulrahman Khormi2, Marcela Munoz-Urbano3, Shirish Sangle1 and David D'Cruz4, 1Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, 2Prince Sattam University Medical College, Al-Kharj, Saudi Arabia, 3Clínica Imbanaco, Cali, Colombia, 4Guy’s Hospital, Louise Coote Lupus Unit, London, United Kingdom

    Background/Purpose: Takayasu arteritis (TA) is a large-vessel vasculitis which primarily affects the aorta and its main branches. Accurate assessment of disease activity has always been…
  • Abstract Number: 1725 • ACR Convergence 2023

    Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model

    Yue Peng1, H. Mark Kenney2, Karen Bentley3, Lianping Xing4, Christopher T Ritchlin5 and Edward Schwarz3, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Henrietta, NY, 3University of Rochester, Rochester, NY, 4University of Rochester Medical Center, Webster, NY, 5University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

    Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
  • Abstract Number: 1690 • ACR Convergence 2023

    Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study

    Mikkel Østergaard1, Walter P. Maksymowych2, Mikael Boesen3, Robert Lambert4, Guillermo Valenzuela5, Michael Bubb6, Olga Kubassova7, Jyotsna Reddy8, Stephen Colgan9, Yuri Klyachkin10, Cynthia Deignan11, Lihua Tang8, Maria Paris8 and Philip J. Mease12, 1Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, 2University of Alberta, Edmonton, AB, Canada, 3Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Naerum, Denmark, 4Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, AB, Canada, 5Integral Rheumatology & Immunology Specialists, Plantation, FL, 6University of Florida, Gainesville, FL, 7Image Analysis Group, Philadelphia, PA, 8Amgen, Inc., Thousand Oaks, CA, 9Amgen, Inc., Halton Hills, ON, Canada, 10Amgen, Inc., Lexington, KY, 11Amgen, Inc., Agoura Hills, CA, 12Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA

    Background/Purpose: PsA is characterized by inflammatory arthritis, enthesitis, dactylitis, and spondylitis. Apremilast (APR) is an oral immunomodulating phosphodiesterase-4 inhibitor approved for the treatment of PsA.…
  • Abstract Number: 1577 • ACR Convergence 2023

    Analysis of Takayasu’s Arteritis as Risk Factor for Acute Coronary Syndrome

    Maria Romero Noboa1, Shilpa Arora1 and Augustine Manadan2, 1John H. Stroger Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL

    Background/Purpose: Takayasu's arteritis (TAK) is an autoimmune disease that primarily affects the aorta and its major branches. It has an incidence of 1-3 per million…
  • Abstract Number: 1155 • ACR Convergence 2023

    Identification of Serum Biomarkers Associated with Muscle Damage Detected on MRI in Polymyositis/dermatomyositis

    Haruna Matsuo1, Toshimasa Shimizu2, Tomohiro Koga3, Nozomi Oki4, Mari Kamiya5, Natsuka Umezawa5, Shinsuke Yasuda6, Masataka Uetani7 and Atsushi Kawakami8, 1Nagasaki University, Nagasaki City, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University, Nagasaki, Japan, 4Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan, 5Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 6Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, 7Department of Radiological Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 8Nagasaki University, Nagasaki, Japan

    Background/Purpose: Polymyositis/Dermatomyositis (PM/DM) is a chronic inflammatory disease characterized by muscle weakness, and cutaneous manifestations. Although PM/DM exhibits distinct disease phenotypes based on autoantibodies, assessing…
  • Abstract Number: 1578 • ACR Convergence 2023

    Impact of Anxiety or Depression Status and Fibromyalgia on Adherence to Treatment of Patients with Takayasu Arteritis

    Alejandra Espinosa-Orantes1, David Vera-Bustamante2, Jessica Roldan Ortega3, Maria Mejia-Avila4, Jose Raul Molina5, Evelyn Aranda Cano5, Adriana Miguel-Alvarez5, Ismael Valenzuela5, Viridiana Del Río-Guerrero6, Paloma Rodriguez5, Mauricio Mora-Ramirez5, Nilda Espinola-Zavaleta4, Luis H Silveira-torre6, Angélica Vargas Guerrero7 and Laura A Martínez-Martínez8, 1Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, 2BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA, Mexico City, Mexico, 3INSTITUTO NACIONAL DE CARDIOLOGIA, Ciudad de México, Mexico, 4Instituto Nacional de Cardiologia Ignacio Chavez, Mexico City, Mexico, 5Instituto Nacional de Cardiologia, Mexico City, Mexico, 6Instituto Nacional de Cardiología, Mexico City, Mexico, 7Instituto Nacional de Cardiología, Mexico City, Mexico, 8Universidad Nacional Autónoma de México - Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico

    Background/Purpose: Takayasu arteritis (TAK) is a chronic, granulomatous large-vessel vasculitis. As TAK has a chronic course, higher frequency rates of anxiety and depression are reported…
  • Abstract Number: 1590 • ACR Convergence 2023

    Autoimmune Pathway Blockade by a Potent Orally Bioavailable STING Antagonist

    Min Yang1, Hailong Li1, yangyang liu1, lili yao1, Jing Lin1, Zhi xie2 and Wenge zhong1, 1Regor Therapeutics, Shanghai, China, 2Regor Pharmaceuticals, Inc., San Francisco, CA

    Background/Purpose: The cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway has emerged as a key innate immune mediator of autoimmune and inflammatory diseases. However,…
  • « Previous Page
  • 1
  • …
  • 439
  • 440
  • 441
  • 442
  • 443
  • …
  • 2605
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology